Camurus AB

Camurus is a science-led, global biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for patients with severe and chronic diseases. The company leverages its proprietary FluidCrystal® technology—a lipid-based drug delivery system—to create injectable depots that provide sustained therapeutic levels of medication over extended periods, ranging from days to months. Headquartered in Lund, Sweden, with expanding operations in the US, Europe, and Australia, Camurus focuses on therapeutic areas including Central Nervous System (CNS) disorders, rare diseases, endocrinology, oncology, and supportive care. The company has a validated commercial infrastructure and a diversified R&D pipeline, both in-house and through strategic partnerships with international pharmaceutical companies.